$BDSX News

Biodesix to Report Third Quarter 2026 Financial Results on November 5, 2026

American College of Chest Physicians Publishes New Framework for Lung Nodule Programs Recommending Biomarkers for Risk Stratification

Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers

Biodesix Adds AI-Powered Imaging Test To Expand Lung Cancer Risk Screening

Biodesix (BDSX) Stock Sees Fair Value Lift As Analysts Back MRD Growth

TD Cowen Maintains Buy on Biodesix, Raises Price Target to $40

Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026

Biodesix Announces Multiple Presentations At CHEST 2026 Highlighting How Nodify Lung Testing Is Being Incorporated Into Real-World Lung Nodule Management

Biodesix Announces Progress In Two Collaborative Programs For Tumor-informed And Tumor-naïve Molecular Residual Disease Solutions

Biodesix (BDSX) Stock Gets Fair Value Boost On Revenue And Margin Optimism

Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings

Biodesix: Growing Fast While Trading Below Many Diagnostics Peers

Biodesix to Participate in Upcoming Investor Conferences

BioDesix (NASDAQ:BDSX) Passes Minervini Trend Template but Setup Quality Remains Weak

What Makes Biodesix, Inc. (BDSX) a Strong Momentum Stock: Buy Now?

Wall Street Analysts See a 26.72% Upside in Biodesix (BDSX): Can the Stock Really Move This High?

PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?

Biodesix (BDSX) Q2 2026 Earnings Call Transcript

Biodesix Sees Nodify Growth, Reaffirms Revenue Outlook at Canaccord Conference

Biodesix, Inc. (BDSX) Hit a 52 Week High, Can the Run Continue?